Your browser is no longer supported. Please, upgrade your browser.
PRQR ProQR Therapeutics N.V. daily Stock Chart
PRQR [NASD]
ProQR Therapeutics N.V.
Index- P/E- EPS (ttm)-1.45 Insider Own8.56% Shs Outstand49.91M Perf Week2.02%
Market Cap287.84M Forward P/E- EPS next Y-2.01 Insider Trans0.00% Shs Float45.71M Perf Month4.71%
Income-63.90M PEG- EPS next Q-0.36 Inst Own72.30% Short Float1.18% Perf Quarter-21.58%
Sales1.90M P/S151.50 EPS this Y-27.00% Inst Trans-1.59% Short Ratio2.68 Perf Half Y-33.97%
Book/sh1.80 P/B3.09 EPS next Y-21.50% ROA-59.50% Target Price- Perf Year-55.41%
Cash/sh2.07 P/C2.68 EPS next 5Y- ROE-76.10% 52W Range4.46 - 12.92 Perf YTD-43.90%
Dividend- P/FCF- EPS past 5Y-21.50% ROI-53.40% 52W High-56.97% Beta0.50
Dividend %- Quick Ratio11.00 Sales past 5Y43.90% Gross Margin- 52W Low24.66% ATR0.37
Employees154 Current Ratio11.00 Sales Q/Q-25.00% Oper. Margin- RSI (14)53.00 Volatility5.59% 7.32%
OptionableYes Debt/Eq0.17 EPS Q/Q11.60% Profit Margin- Rel Volume0.51 Prev Close5.60
ShortableYes LT Debt/Eq0.16 EarningsFeb 26 Payout- Avg Volume201.27K Price5.56
Recom1.70 SMA204.33% SMA503.91% SMA200-22.24% Volume101,688 Change-0.71%
Mar-12-19Reiterated Chardan Capital Markets Buy $21 → $25
Dec-19-18Initiated RBC Capital Mkts Outperform
Nov-15-18Initiated Citigroup Buy $32
Sep-19-18Initiated Evercore ISI Outperform
Sep-26-17Reiterated JMP Securities Mkt Outperform $14 → $20
Jun-20-16Initiated Chardan Capital Markets Neutral $4.50
Oct-15-14Initiated Deutsche Bank Buy $32
Oct-13-14Initiated H.C. Wainwright Buy $40
May-29-20 08:55AM  How ProQR (PRQR) Stock Stands Out in a Strong Industry Zacks
May-25-20 07:00AM  ProQR Announces Annual Meeting of Shareholders GlobeNewswire
May-07-20 08:55AM  ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates Zacks
07:00AM  ProQR Announces First Quarter 2020 Operating and Financial Results GlobeNewswire
Apr-28-20 08:47AM  Does ProQR Therapeutics (NASDAQ:PRQR) Have A Healthy Balance Sheet? Simply Wall St.
Mar-31-20 06:00AM  ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update GlobeNewswire -20.20%
Mar-25-20 04:15PM  ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome GlobeNewswire -5.41%
Mar-05-20 08:29AM  Editas, Allergan Start Dosing in Early-Stage Eye Disease Study Zacks
Feb-28-20 11:23AM  How Much Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Pocket Last Year? Simply Wall St.
Feb-26-20 07:00AM  ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update GlobeNewswire
Feb-24-20 07:00AM  ProQR to Present at Cowen and Company 40th Annual Health Care Conference GlobeNewswire -6.42%
Feb-06-20 07:00AM  ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases GlobeNewswire +10.51%
Jan-30-20 07:00AM  ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a GlobeNewswire -7.47%
Jan-21-20 04:09AM  3 Healthcare Stocks That Can Double in the Next Year TipRanks +5.35%
Jan-06-20 09:45AM  Editas (EDIT) Focuses on Developing Eye Candidate EDIT-101 Zacks
Dec-23-19 11:51AM  Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 119%? Simply Wall St. +6.33%
Dec-17-19 05:20PM  Did Hedge Funds Drop The Ball On ProQR Therapeutics NV (PRQR) ? Insider Monkey -8.75%
Dec-12-19 03:19PM  ProQR (PRQR) Begins Dosing in Phase I/II Eye Disorder Study Zacks +10.89%
Dec-11-19 02:42PM  Vertex's Kalydeco Gets EU Approval to Treat CF in Infants Zacks
07:00AM  ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa GlobeNewswire
Nov-21-19 08:25AM  ProQR shares rises on FDA orphan drug designation MarketWatch +6.37%
07:00AM  ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa GlobeNewswire
Nov-18-19 07:23AM  ProQR to Present at Upcoming Scientific Conferences GlobeNewswire -9.29%
Nov-13-19 07:00AM  ProQR to Present at Upcoming Investor Conferences GlobeNewswire +5.39%
Nov-06-19 06:09PM  Were Hedge Funds Right About Dumping ProQR Therapeutics NV (PRQR)? Insider Monkey
11:24AM  Blueprint Medicines (BPMC) Q3 Earnings & Sales Top Estimates Zacks
08:55AM  ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates Zacks
07:00AM  ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019 GlobeNewswire
Nov-05-19 11:45AM  Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates Zacks
Oct-24-19 12:50PM  BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3 Zacks
Oct-23-19 07:42AM  Will ProQR Therapeutics Continue to Surge Higher? Zacks
Oct-18-19 08:20AM  ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -5.01%
Oct-16-19 07:06AM  The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga
Oct-15-19 11:17PM  ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares GlobeNewswire
04:13PM  ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares GlobeNewswire
04:08PM  ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 GlobeNewswire
Oct-10-19 07:31AM  The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO Benzinga
06:00AM  ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients GlobeNewswire
Oct-07-19 07:00AM  ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO GlobeNewswire
Oct-01-19 09:09AM  ProQR Therapeutics Enters Oversold Territory Zacks
Sep-30-19 07:00AM  ProQR to Present at Two Investor Conferences in October GlobeNewswire -7.10%
Sep-24-19 10:33AM  Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt? Simply Wall St.
Sep-13-19 11:08AM  Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland Zacks
Sep-09-19 07:00AM  ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa GlobeNewswire
Aug-14-19 12:18PM  Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study Zacks -8.05%
Aug-13-19 11:53AM  Mallinckrodt Enrolls First Patient in Liver Disease Study Zacks
Aug-12-19 07:00AM  ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) GlobeNewswire
Aug-07-19 10:05AM  ProQR (PRQR) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM  ProQR Announces Financial Results for the Second Quarter of 2019 GlobeNewswire
Jul-29-19 07:00AM  European Medicines Agency Grants PRIME Access to ProQRs Sepofarsen for Lebers Congenital Amaurosis 10 GlobeNewswire
Jul-26-19 01:31PM  What Did ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Take Home Last Year? Simply Wall St.
Jul-02-19 07:00AM  ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July GlobeNewswire
Jun-29-19 05:34PM  Heres What Hedge Funds Think About ProQR Therapeutics NV (PRQR) Insider Monkey
Jun-03-19 07:00AM  ProQR to Present at the JMP Securities Life Sciences Conference GlobeNewswire
May-27-19 10:56AM  Did Business Growth Power ProQR Therapeutics's (NASDAQ:PRQR) Share Price Gain of 153%? Simply Wall St.
May-15-19 07:00AM  ProQR to Present at the RBC Capital Markets Healthcare Conference GlobeNewswire
May-08-19 02:29PM  Here is What Hedge Funds Think About ProQR Therapeutics NV (PRQR) Insider Monkey
08:45AM  ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:34AM  ProQR: 1Q Earnings Snapshot Associated Press
07:00AM  ProQR Announces Financial Results for the First Quarter of 2019 GlobeNewswire
Apr-22-19 07:00AM  ProQR to Present at Three Scientific Conferences in April GlobeNewswire
Apr-18-19 07:00AM  ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board GlobeNewswire
07:00AM  ProQR Announces Annual Meeting of Shareholders GlobeNewswire
Apr-16-19 07:26PM  ProQR Initiates Dosing in Phase II/III Eye Disorder Study Zacks -7.38%
Apr-15-19 07:00AM  ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 GlobeNewswire
Apr-01-19 07:00AM  ProQR to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-26-19 04:01PM  ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership GlobeNewswire
Mar-11-19 08:00AM  ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 GlobeNewswire
Mar-05-19 07:00AM  ProQR to Present at Cowen Health Care Conference GlobeNewswire
Feb-28-19 09:50AM  Medicines Company (MDCO) Q4 Loss Widens, Inclisiran in Focus Zacks
Feb-27-19 07:00AM  ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results GlobeNewswire
Feb-21-19 09:34AM  Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer Zacks
Jan-29-19 10:11AM  Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids Zacks
08:30AM  ProQR Announces ProQR Vision 2023 Strategy at its Annual R&D Day GlobeNewswire
Jan-22-19 10:44AM  Should You Worry About ProQR Therapeutics N.V.s (NASDAQ:PRQR) CEO Salary Level? Simply Wall St.
Jan-07-19 07:00AM  ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Lebers Congenital Amaurosis 10 GlobeNewswire
Jan-03-19 09:51AM  Company News For Jan 3, 2019 Zacks
07:00AM  ProQR to Host R&D Day in New York on January 29 GlobeNewswire
Jan-02-19 11:10AM  Best Sector of 2018 and its Hit ETFs & Stocks Zacks +10.77%
07:00AM  ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 GlobeNewswire
Dec-24-18 07:00AM  ProQR Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-23-18 04:31AM  Is ProQR Therapeutics NV (PRQR) Going to Burn These Hedge Funds? Insider Monkey
Dec-17-18 11:52AM  ProQR Announces Publication in Nature Medicine of QR-110 Data for Lebers Congenital Amaurosis 10 GlobeNewswire
Dec-13-18 07:00AM  ProQR Announces Strategic Changes to the Management Team and Key New Hires GlobeNewswire
Dec-10-18 07:00AM  ProQR Receives 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 GlobeNewswire -5.11%
Dec-04-18 07:00AM  ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients GlobeNewswire
Nov-20-18 07:00AM  ProQR to Present at the Evercore ISI HealthConX Conference GlobeNewswire
Nov-16-18 08:55AM  Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-07-18 08:45AM  ProQR (PRQR) Reports Q3 Loss, Misses Revenue Estimates Zacks -5.23%
07:37AM  ProQR: 3Q Earnings Snapshot Associated Press
07:00AM  ProQR Announces Financial Results for the Third Quarter of 2018 GlobeNewswire
Oct-31-18 07:00AM  ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference GlobeNewswire
Oct-29-18 07:33AM  ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals GlobeNewswire
Oct-16-18 02:39PM  Shareholders Should Check The Ownership Structure Of ProQR Therapeutics NV (NASDAQ:PRQR) Simply Wall St.
Oct-02-18 07:00AM  ProQR to Present at the Chardan Genetic Medicines Conference GlobeNewswire
Sep-24-18 07:00AM  ProQR Announces Presentations at the OTS Annual Meeting GlobeNewswire
Sep-12-18 10:41AM  Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars Zacks -14.35%
Sep-11-18 04:01PM  ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +15.82%
Sep-10-18 04:55PM  Why ProQR Therapeutics N.V. Is Soaring Again Today Motley Fool +18.04%
Sep-08-18 07:16AM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.